Pfizer Ramps up Covid-19 Vaccine Production -- 2nd Update
April 13 2021 - 5:23PM
Dow Jones News
By Maria Armental
Pfizer Inc. Chief Executive Albert Bourla said the company
ramped up production of its Covid-19 vaccine and will be able to
deliver 10% more doses to the U.S. by the end of May than
previously agreed.
In addition, Mr. Bourla said on Twitter, Pfizer will supply the
full 300 million doses agreed on for the end of July two weeks
early.
"In the fight against COVID-19, we're in this together," he
tweeted Tuesday.
Moderna Inc. on Tuesday said it remained on track to deliver the
second 100 million doses to the U.S. government by the end of May
and another 100 million doses by the end of July.
The supply chain outside of the U.S. was established
approximately one quarter behind the U.S. supply chain and
continues to ramp up, Moderna said.
On Tuesday, U.S. health authorities recommended pausing the use
of Johnson & Johnson's Covid-19 vaccine to look into reports of
rare but severe cases of blood clots.
J&J's vaccine uses similar technology as a vaccine from
AstraZeneca PLC and the University of Oxford, which hasn't been
authorized in the U.S. and has also been linked to rare cases of
blood clots.
The U.S. has an abundant supply of the Pfizer-BioNTech and
Moderna vaccines, a Health and Human Services Department official
said.
-- Peter Loftus and Thomas M. Burton contributed to this
story.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
April 13, 2021 17:08 ET (21:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024